Article

Assessment of Myocardial Scarring Improves Risk Stratification in Patients Evaluated for Cardiac Defibrillator Implantation

Duke Cardiovascular Magnetic Resonance Center, Duke University Medical Center, Durham, NC 27710, USA.
Journal of the American College of Cardiology (Impact Factor: 15.34). 07/2012; 60(5):408-20. DOI: 10.1016/j.jacc.2012.02.070
Source: PubMed

ABSTRACT We tested whether an assessment of myocardial scarring by cardiac magnetic resonance imaging (MRI) would improve risk stratification in patients evaluated for implantable cardioverter-defibrillator (ICD) implantation.
Current sudden cardiac death risk stratification emphasizes left ventricular ejection fraction (LVEF); however, most patients suffering sudden cardiac death have a preserved LVEF, and many with poor LVEF do not benefit from ICD prophylaxis.
One hundred thirty-seven patients undergoing evaluation for possible ICD placement were prospectively enrolled and underwent cardiac MRI assessment of LVEF and scar. The pre-specified primary endpoint was death or appropriate ICD discharge for sustained ventricular tachyarrhythmia.
During a median follow-up of 24 months the primary endpoint occurred in 39 patients. Whereas the rate of adverse events steadily increased with decreasing LVEF, a sharp step-up was observed for scar size >5% of left ventricular mass (hazard ratio [HR]: 5.2; 95% confidence interval [CI]: 2.0 to 13.3). On multivariable Cox proportional hazards analysis, including LVEF and electrophysiological-study results, scar size (as a continuous variable or dichotomized at 5%) was an independent predictor of adverse outcome. Among patients with LVEF >30%, those with significant scarring (>5%) had higher risk than those with minimal or no (≤5%) scarring (HR: 6.3; 95% CI: 1.4 to 28.0). Those with LVEF >30% and significant scarring had risk similar to patients with LVEF ≤30% (p = 0.56). Among patients with LVEF ≤30%, those with significant scarring again had higher risk than those with minimal or no scarring (HR: 3.9; 95% CI: 1.2 to 13.1). Those with LVEF ≤30% and minimal scarring had risk similar to patients with LVEF >30% (p = 0.71).
Myocardial scarring detected by cardiac MRI is an independent predictor of adverse outcome in patients being considered for ICD placement. In patients with LVEF >30%, significant scarring (>5% LV) identifies a high-risk cohort similar in risk to those with LVEF ≤30%. Conversely, in patients with LVEF ≤30%, minimal or no scarring identifies a low-risk cohort similar to those with LVEF >30%.

Download full-text

Full-text

Available from: Michele Parker, Dec 29, 2014
4 Followers
 · 
148 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Cardiovascular involvement in systemic inflammatory diseases (SID) is underestimated despite its high mortality and morbidity. SID with cardiovascular involvement includes rheumatoid arthritis and the spondyloarthropathies, systemic lupus erythematosus, systemic vasculitides, inflammatory myopathies, systemic sclerosis, mixed connective tissue diseases (MCTD) and sarcoidosis (SRC). Cardiovascular magnetic resonance (CMR) is of great value in SID because myocardial inflammation, diffuse, subendocardial vasculitis and small scars due to inflammation or myocardial infarction and heart disease acuity can be detected neither by echocardiography nor by nuclear techniques; finally, most patients are unable to exercise adequately, and pharmacologic stress CMR is the best technique for coronary artery and cardiac microvascular disease assessment. However, lack of availability, expertise and high cost constitute serious obstacles for the routine application of CMR in every day practice.
    Current Cardiovascular Imaging Reports 03/2015; 8(3). DOI:10.1007/s12410-015-9319-z
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Sudden death accounts for 300,000-400,000 deaths annually in the United States. Most sudden deaths are cardiac, and most sudden cardiac deaths are related to arrhythmias secondary to structural heart disease or primary electrical abnormalities of the heart. The most common structural disease leading to sudden death is ischemic heart disease. Nonischemic cardiomyopathy and other structural abnormalities such as arrhythmogenic ventricular dysplasia and hypertrophic cardiomyopathy may also be causative. Patients without structural disease have a primary electrical abnormality, such as long-QT syndrome or Brugada syndrome. Severe left ventricular systolic dysfunction is the main marker for sudden death in patients with ischemic or nonischemic cardiomyopathy. In other conditions, other markers for structural heart disease and electrical abnormalities need to be considered. It is seen that β-blocker therapy is associated with a reduction in sudden cardiac death across a broad range of disorders. Nevertheless, the implantable cardioverter defibrillator remains the most effective treatment strategy in selected patients. Copyright © 2015 Elsevier Inc. All rights reserved.
    Current Problems in Cardiology 02/2015; 40(4). DOI:10.1016/j.cpcardiol.2015.01.002 · 2.17 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Important advances have been made in the past few years in the fields of clinical cardiac electrophysiology and pacing. Researchers and clinicians have a greater understanding of the pathophysiological mechanisms underlying atrial fibrillation (AF), which has transpired into improved methods of detection, risk stratification, and treatments. The introduction of novel oral anticoagulants has provided clinicians with alternative options in managing patients with AF at moderate to high thromboembolic risk and further data has been emerging on the use of catheter ablation for the treatment of symptomatic AF. Another area of intense research in the field of cardiac arrhythmias and pacing is in the use of cardiac resynchronisation therapy (CRT) for the treatment of patients with heart failure. Following the publication of major landmark randomised controlled trials reporting that CRT confers a survival advantage in patients with severe heart failure and improves symptoms, many subsequent studies have been performed to further refine the selection of patients for CRT and determine the clinical characteristics associated with a favourable response. The field of sudden cardiac death and implantable cardioverter defibrillators also continues to be actively researched, with important new epidemiological and clinical data emerging on improved methods for patient selection, risk stratification, and management. This review covers the major recent advances in these areas related to cardiac arrhythmias and pacing.
    Anadolu kardiyoloji dergisi: AKD = the Anatolian journal of cardiology 09/2013; 99(19). DOI:10.5152/akd.2013.233 · 0.76 Impact Factor